Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy for head and neck cancer: where are we now and where are we going?

Literature DB >> 31576284

Immunotherapy for head and neck cancer: where are we now and where are we going?

Joshua M Bauml¹, Charu Aggarwal¹, Roger B Cohen¹.

Abstract

Entities: Disease

Year: 2019 PMID： 31576284 PMCID： PMC6685871 DOI： 10.21037/atm.2019.03.58

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

20 in total

1. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.

Authors: Mark L Bagarazzi; Jian Yan; Matthew P Morrow; David B Weiner; Niranjan Y Sardesai; Xuefei Shen; R Lamar Parker; Jessica C Lee; Mary Giffear; Panyupa Pankhong; Amir S Khan; Kate E Broderick; Christine Knott; Feng Lin; Jean D Boyer; Ruxandra Draghia-Akli; C Jo White; J Joseph Kim
Journal: Sci Transl Med Date: 2012-10-10 Impact factor: 17.956

2. Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors: Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal: N Engl J Med Date: 2014-11-19 Impact factor: 91.245

3. Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544

4. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Authors: Nadeem Riaz; Jonathan J Havel; Vladimir Makarov; Alexis Desrichard; Walter J Urba; Jennifer S Sims; F Stephen Hodi; Salvador Martín-Algarra; Rajarsi Mandal; William H Sharfman; Shailender Bhatia; Wen-Jen Hwu; Thomas F Gajewski; Craig L Slingluff; Diego Chowell; Sviatoslav M Kendall; Han Chang; Rachna Shah; Fengshen Kuo; Luc G T Morris; John-William Sidhom; Jonathan P Schneck; Christine E Horak; Nils Weinhold; Timothy A Chan
Journal: Cell Date: 2017-10-12 Impact factor: 41.582

5. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors: Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal: J Thorac Oncol Date: 2016-11-29 Impact factor: 15.609

6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal: Science Date: 2015-03-12 Impact factor: 47.728

7. Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors: Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Journal: N Engl J Med Date: 2008-09-11 Impact factor: 91.245

8. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.

Authors: Charu Aggarwal; Roger B Cohen; Matthew P Morrow; Kimberly A Kraynyak; Albert J Sylvester; Dawson M Knoblock; Joshua M Bauml; Gregory S Weinstein; Alexander Lin; Jean Boyer; Lindsay Sakata; Sophie Tan; Aubrey Anton; Kelsie Dickerson; Drishty Mangrolia; Russell Vang; Michael Dallas; Sandra Oyola; Susan Duff; Mark Esser; Rakesh Kumar; David Weiner; Ildiko Csiki; Mark L Bagarazzi
Journal: Clin Cancer Res Date: 2018-09-21 Impact factor: 12.531

9. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245

10. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Authors: Ari Vanderwalde; David Spetzler; Nianqing Xiao; Zoran Gatalica; John Marshall
Journal: Cancer Med Date: 2018-02-13 Impact factor: 4.452

12 in total

Review 1. Management of squamous cell carcinomas of the skull-base.

Authors: Colin G Leonard; Vikram Padhye; Ian J Witterick
Journal: J Neurooncol Date: 2020-06-05 Impact factor: 4.130

Review 2. Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.

Authors: Jong Chul Park; Hari N Krishnakumar; Srinivas Vinod Saladi
Journal: Curr Oncol Date: 2022-06-08 Impact factor: 3.109

Review 3. Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review).

Authors: Annette Affolter; Johann Kern; Karen Bieback; Claudia Scherl; Nicole Rotter; Anne Lammert
Journal: Int J Oncol Date: 2022-06-01 Impact factor: 5.884

4. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.

Authors: Haitao Wang; Shanji Nan; Ying Wang; Chengbi Xu
Journal: J Cell Mol Med Date: 2021-03-17 Impact factor: 5.310

5. Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas.

Authors: Giacomo Miserocchi; Claudia Cocchi; Alessandro De Vita; Chiara Liverani; Chiara Spadazzi; Sebastiano Calpona; Giandomenico Di Menna; Massimo Bassi; Giuseppe Meccariello; Giovanni De Luca; Angelo Campobassi; Maria Maddalena Tumedei; Alberto Bongiovanni; Valentina Fausti; Franco Cotelli; Toni Ibrahim; Laura Mercatali
Journal: Cancer Biol Med Date: 2021-03-27 Impact factor: 4.248

6. Synergies Radiotherapy-Immunotherapy in Head and Neck Cancers. A New Concept for Radiotherapy Target Volumes-"Immunological Dose Painting".

Authors: Camil Ciprian Mireştean; Anda Crişan; Călin Buzea; Roxana Irina Iancu; DragoşPetru Teodor Iancu
Journal: Medicina (Kaunas) Date: 2020-12-23 Impact factor: 2.430

Review 7. MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?

Authors: Juliane Hörner-Rieber; Sebastian Klüter; Jürgen Debus; Gosse Adema; Marleen Ansems; Marcel Verheij
Journal: Front Oncol Date: 2021-02-02 Impact factor: 6.244

8. Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.

Authors: Rosalinda Arends; Xiang Guo; Paul G Baverel; Ignacio González-García; James Xie; Nassim Morsli; Alejandro Yovine; Lorin K Roskos
Journal: Oncoimmunology Date: 2021-03-17 Impact factor: 8.110

9. Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.

Authors: Rex H Lee; Hyunseok Kang; Sue S Yom; Agata Smogorzewska; Daniel E Johnson; Jennifer R Grandis
Journal: Clin Cancer Res Date: 2021-10-01 Impact factor: 12.531

Review 10. Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors.

Authors: Alejandro Olivares-Hernández; Luis Figuero-Pérez; José Pablo Miramontes-González; Álvaro López-Gutiérrez; Rogelio González-Sarmiento; Juan Jesús Cruz-Hernández; Emilio Fonseca-Sánchez
Journal: Life (Basel) Date: 2021-12-15